253 related articles for article (PubMed ID: 2547935)
61. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat.
Diop L; Rivière PJ; Pascaud X; Junien JL
Eur J Pharmacol; 1994 Dec; 271(1):65-71. PubMed ID: 7698213
[TBL] [Abstract][Full Text] [Related]
62. Kappa agonist-induced reduction in dopamine release: site of action and tolerance.
Donzanti BA; Althaus JS; Payson MM; Von Voigtlander PF
Res Commun Chem Pathol Pharmacol; 1992 Nov; 78(2):193-210. PubMed ID: 1282270
[TBL] [Abstract][Full Text] [Related]
63. Enhancement of a kappa-opioid receptor agonist-induced analgesia by L-tyrosine and L-tryptophan.
Barjavel MJ; Thorat SN; Bhargava HN
Eur J Pharmacol; 1994 Jun; 258(3):173-8. PubMed ID: 8088353
[TBL] [Abstract][Full Text] [Related]
64. Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions.
Chang HM; Berde CB; Holz GG; Steward GF; Kream RM
Anesthesiology; 1989 Apr; 70(4):672-7. PubMed ID: 2467589
[TBL] [Abstract][Full Text] [Related]
65. Nitric oxide synthase inhibition blocks tolerance to the analgesic action of kappa-opiate receptor agonist in the rat.
Bhargava HN
Pharmacology; 1994 Apr; 48(4):234-41. PubMed ID: 7513892
[TBL] [Abstract][Full Text] [Related]
66. [Synthesis and analgesic activity of analogs of U-50488, an opiate kappa-agonist].
Ma SC; Yang YL; Yuan XM
Yao Xue Xue Bao; 1991; 26(12):902-5. PubMed ID: 1668563
[TBL] [Abstract][Full Text] [Related]
67. Inhibition of [3H][3-MeHis2]thyrotropin releasing hormone recognition sites in the rat brain by tifluadom, a kappa opiate receptor agonist.
Das S; Bhargava HN
Neuropharmacology; 1987 Aug; 26(8):1141-6. PubMed ID: 2889163
[TBL] [Abstract][Full Text] [Related]
68. Disability of development of tolerance to morphine and U-50,488H, a selective kappa-opioid receptor agonist, in neuropathic pain model mice.
Sounvoravong S; Takahashi M; Nakashima MN; Nakashima K
J Pharmacol Sci; 2004 Mar; 94(3):305-12. PubMed ID: 15037816
[TBL] [Abstract][Full Text] [Related]
69. Effects of chronic U50,488H treatment on binding and mechanical responses of the rat hearts.
Xia Q; Sheng JZ; Tai KK; Wong TM
J Pharmacol Exp Ther; 1994 Feb; 268(2):930-4. PubMed ID: 8114007
[TBL] [Abstract][Full Text] [Related]
70. Kappa opioid receptors stimulate phosphoinositide turnover in rat brain.
Periyasamy S; Hoss W
Life Sci; 1990; 47(3):219-25. PubMed ID: 1975082
[TBL] [Abstract][Full Text] [Related]
71. Possible mechanism involved in the inhibitory action of U-50, 488H, an opioid kappa agonist, on guinea pig hippocampal CA3 pyramidal neurons in vitro.
Iwama T; Ishihara K; Takagi H; Satoh M
J Pharmacobiodyn; 1987 Oct; 10(10):564-70. PubMed ID: 3326929
[TBL] [Abstract][Full Text] [Related]
72. Antinociceptive effects of the kappa opioid, U50,488: lack of modulation by 5-HT2 antagonists.
Dykstra LA; Powell KR; Lin YP
Psychopharmacology (Berl); 1993; 112(1):116-20. PubMed ID: 7870999
[TBL] [Abstract][Full Text] [Related]
73. Effects of a kappa-receptor agonist, U-50,488H, on the release of endogenous brain dopamine.
Clow DW; Jhamandas K
Can J Physiol Pharmacol; 1988 Feb; 66(2):128-33. PubMed ID: 2836044
[TBL] [Abstract][Full Text] [Related]
74. The abilities of specific kappa-opioid agonists, U-50,488H and U-62,066E, to cause antitussive tolerance were lower than that of morphine.
Kamei J; Tanihara H; Kasuya Y
Jpn J Pharmacol; 1991 Aug; 56(4):557-61. PubMed ID: 1744997
[TBL] [Abstract][Full Text] [Related]
75. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action.
Czlonkowski A; Millan MJ; Herz A
Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175
[No Abstract] [Full Text] [Related]
76. Effects of the selective kappa-opioid receptor agonist U-50,488 on locomotor activity and passive avoidance behaviour in DBA/2 and C57BL/6 mice.
Castellano C; Pavone F
Arch Int Pharmacodyn Ther; 1987 Aug; 288(2):270-80. PubMed ID: 2823735
[TBL] [Abstract][Full Text] [Related]
77. Properties of a selective kappa agonist, U-50,488H.
Lahti RA; VonVoigtlander PF; Barsuhn C
Life Sci; 1982 Nov 15-22; 31(20-21):2257-60. PubMed ID: 6131357
[TBL] [Abstract][Full Text] [Related]
78. Haloperidol pretreatment unmasks the kappa opioid effects of U-50, 488H on cortical EEG and EEG power spectra in rats.
Young GA; Marquis KL; Paquette NC; Gussio RP; Khazan N
Neuropharmacology; 1989 Aug; 28(8):881-4. PubMed ID: 2550842
[TBL] [Abstract][Full Text] [Related]
79. Chronic administration of U50,488H fails to produce hypothalamo-pituitary-adrenal axis tolerance in neonatal rats.
Ignar DM; Windh RT; Kuhn CM
Neuropharmacology; 1992 Feb; 31(2):143-8. PubMed ID: 1553027
[TBL] [Abstract][Full Text] [Related]
80. Dose related effects of the kappa agonist U-50, 488H on behaviour, nociception and autonomic response in the horse.
Kamerling S; Weckman T; Donahoe J; Tobin T
Equine Vet J; 1988 Mar; 20(2):114-8. PubMed ID: 3286243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
